Venture(US:VEMLY) Mei Ri Jing Ji Xin Wen·2025-11-06 14:15Core Viewpoint - The long-standing divorce dispute between Zhao Bingxian, known as "China's Buffett," and his ex-wife Lu Juan has concluded with a court ruling on the division of their assets, specifically regarding their stake in Zhongzheng Wanrong Investment Group, valued at 10 billion yuan [1][2]. Group 1: Court Ruling and Financial Implications - The Beijing Third Intermediate People's Court ruled that Zhao Bingxian and Lu Juan will equally split their shares in Zhongzheng Wanrong, resulting in each holding 50% of the equity [2][4]. - The court's decision does not affect Zhongzheng Wanrong's 50.27% stake in Wohuayi Pharmaceutical, which remains the controlling shareholder of the company [3][4]. - Following the ruling, Zhao Bingxian's "divorce settlement" amounts to 536 million yuan, based on the company's market capitalization of 3.556 billion yuan as of November 6 [4][5]. Group 2: Company Background and Performance - Wohuayi Pharmaceutical specializes in cardiovascular traditional Chinese medicine, with several patented products and a significant number of items listed in national medical insurance directories [5]. - For the first three quarters of 2025, Wohuayi Pharmaceutical reported revenues of 625 million yuan, an increase of 8.31% year-on-year, and a net profit of 63.995 million yuan, up 179.34% [5]. - The company continues to operate normally, with Zhao Bingxian retaining his roles as chairman and legal representative of both Zhongzheng Wanrong and Wohuayi Pharmaceutical [5].